Results 61 to 70 of about 27,690 (216)

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Status epilepticus: Updates on mechanisms and treatments

Epilepsia Open, EarlyView.
Abstract Status epilepticus (SE) consists of prolonged, self‐sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super‐refractory SE.
Suchitra Joshi, Jaideep Kapur
wiley   +1 more source

Ketone Bodies in Diabetes Mellitus: Friend or Foe? [PDF]

Nutrients, 2023
Veneti S, Grammatikopoulou MG, Kintiraki E, Mintziori G, Goulis DG.   +4 more
europepmc   +1 more source

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source

Ketone Bodies Preserve Mitochondria Through Epigenetics. [PDF]

JACC Basic Transl Sci, 2023
Mukai R, Sadoshima J.
europepmc   +1 more source

The physiological role of the ketone bodies [PDF]

Biochemical Journal, 1961
openaire   +2 more sources

Ketogenic diet therapy for children with super‐refractory status epilepticus in intensive care: International clinical practice recommendations

Epilepsia Open, EarlyView.
Abstract Objective We aimed to create practical recommendations to support healthcare teams starting ketogenic diet therapy (KDT) for children with super‐refractory status epilepticus in intensive care settings. Methods A literature review was conducted to extract published data on patient selection, diet prescription, diet initiation, monitoring, fine‐
Robyn Blackford, Victoria J. Whiteley, Isobel Hardy, Marisa Armeno, Tessa Bollard, J. Helen Cross, Christin Eltze, Susan George, Charlotte Howard, A. Laura Nijstad, Erin Talzzia, Chris Paget, Samiran Ray, Zoe Simpson, Elizabeth Song‐Pozderac, Agnieszka Szmurlo, Charlene Tan‐Smith, Lisa Vanatta, Elles van der Louw, Natasha E. Schoeler, on behalf of the Ketogenic Dietitians Research Network   +20 more
wiley   +1 more source

A price check on the ketogenic diet for adults with epilepsy in Australia

Epilepsia Open, EarlyView.
Abstract Objective The ketogenic diet is an established and effective treatment for drug‐resistant epilepsy and is an emerging therapy for other conditions. Affordability of therapeutic ketogenic diets for epilepsy has not been well studied. This study aimed to compare weekly cost of ketogenic diets with national dietary guidelines and a typical ...
Lillian King, Jessica Maccarrone, Ashwinpreet Kaur, Susanna Chen, Patrick Kwan, Terence J. O'Brien, Neha Kaul   +6 more
wiley   +1 more source

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

Equine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom, Sanna Truelsen Lindåse, Monika Wartel, Johan Bröjer   +3 more
wiley   +1 more source